These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8746078)

  • 1. Biological effect of active anti-IFN alpha immunization in HIV-infected patients.
    Fall LS; M'Bika JP; Le Coq H; Fouchard M; Astgen A; Bizzini B; Gringeri A; Santagostino E; Burny A; Zagury D
    Biomed Pharmacother; 1995; 49(9):422-8. PubMed ID: 8746078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection.
    Fall LS; Chams V; Le Coq H; Fouchard M; M'Bika JP; Gringeri A; Santagostino E; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):409-16. PubMed ID: 7580835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.
    Gringeri A; Santagostino E; Cusini M; Muça-Perja M; Marinoni A; Mannucci PM; Burny A; Criscuolo M; Lu W; Andrieru JM; Mbika JP; Lachgar A; Fall LS; Chams V; Feldman M; Hermans P; Zagury JF; Bizzini B; Musicco M; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Sep; 13(1):55-67. PubMed ID: 8797687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
    Gringeri A; Musicco M; Hermans P; Bentwich Z; Cusini M; Bergamasco A; Santagostino E; Burny A; Bizzini B; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):358-70. PubMed ID: 10096580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression.
    Gringeri A; Santagostino E; Mannucci PM; Siracusano L; Marinoni A; Criscuolo M; Carcagno M; Fall LS; M'Bika JP; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):381-7. PubMed ID: 7580831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression.
    Künzi MS; Farzadegan H; Margolick JB; Vlahov D; Pitha PM
    J Infect Dis; 1995 Apr; 171(4):822-8. PubMed ID: 7706808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
    Gallo RC; Burny A; Zagury D
    DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.
    Zagury D; Lecoq H; Gervi I; Le Buanec H; Zagury JF; Bizzini B; Burny A; Hermans P; Perja M; Santagostino E; Gringeri A
    Biomed Pharmacother; 1999 Mar; 53(2):90-2. PubMed ID: 10337463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity.
    Skillman DR; Malone JL; Decker CF; Wagner KF; Mapou RL; Liao MJ; Testa D; Meltzer MS
    J Infect Dis; 1996 May; 173(5):1107-14. PubMed ID: 8627061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.
    Adalid-Peralta L; Godot V; Colin C; Krzysiek R; Tran T; Poignard P; Venet A; Hosmalin A; Lebon P; Rouzioux C; Chene G; Emilie D;
    J Leukoc Biol; 2008 Apr; 83(4):1060-7. PubMed ID: 18182457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection.
    Puoti M; Rossi S; Forleo MA; Zaltron S; Spinetti A; Putzolu V; Rodella A; Carosi G
    J Hepatol; 1998 Jul; 29(1):45-52. PubMed ID: 9696491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of recombinant interferon-alpha in human immunodeficiency virus (HIV)-infected individuals.
    Rivero J; Limonta M; Aguilera A; Fraga M; López Saura P
    Biotherapy; 1994; 8(1):23-31. PubMed ID: 7547078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased levels of antibodies against interferon-alpha in HIV-1 positive individuals may be explained by a common immunological epitope on the human interferon-alpha and HIV-1 gp41.
    Chen YH; Stoiber H; Dierich MP
    Immunol Lett; 1997 Jan; 55(1):15-8. PubMed ID: 9093876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS.
    Bizzini B; Volpato I; Lachgar A; Cohen P; Gringeri A
    Biomed Pharmacother; 1999 Mar; 53(2):87-9. PubMed ID: 10337462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease of enhanced interferon alpha levels in sera of HIV-infected and AIDS patients receiving combined antiretroviral therapy.
    Piasecki E; Knysz B; Gasiorowski J; Gładysz A
    Arch Immunol Ther Exp (Warsz); 1999; 47(1):37-44. PubMed ID: 11729827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha.
    Lapenta C; Santini SM; Logozzi M; Spada M; Andreotti M; Di Pucchio T; Parlato S; Belardelli F
    J Exp Med; 2003 Jul; 198(2):361-7. PubMed ID: 12874266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study.
    Emilie D; Burgard M; Lascoux-Combe C; Laughlin M; Krzysiek R; Pignon C; Rudent A; Molina JM; Livrozet JM; Souala F; Chene G; Grangeot-Keros L; Galanaud P; Sereni D; Rouzioux C;
    AIDS; 2001 Jul; 15(11):1435-7. PubMed ID: 11504966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.